Advanced Prostate Cancer VL

Advanced Prostate Cancer Clinic: What’s Changing? - Maha Hussain

Details
Maha Hussain highlights the pearls in the treatment landscape of metastatic hormone-sensitive, castration-resistant, and non-metastatic castration-resistant disease that came out of the last few years in prostate cancer in terms of the evolution of therapeutics. She details a plethora of clinical trials that had led to significant clinical benefit for patients, primarily overall survival advantage...

Understanding Differences in Outcomes of Men with Prostate Cancer Based on Race and Ethnicity - Christopher Logothetis

Details
Christopher Logothetis and Charles Ryan review key takeaways from Christopher Logothetis's Advanced Prostate Cancer Consensus Conference (APCCC 2019) presentation on Ethnicity and Prognosis of Prostate Cancer and the importance in understanding the differences in outcomes of individuals with the disease based on race and ethnicity. In his work Dr. Logothetis prepared for APCCC 2019, he presses the...

Management of Advanced Prostate Cancer in the Middle East - Deborah Mukherji

Details
Deborah Mukherji sits down with Carmel Pezaro at the Advanced Prostate Cancer Consensus Conference (APCCC 2019) to share her perspective on how prostate cancer care in the Middle East, specifically Lebanon, compares to the rest of the globe. They discuss the impact and the potential of genomic testing and the use of novel imaging, such as PSMA PET/CT relevant to work in the Middle East and in Leba...

Aggressive Variant Prostate Cancer: Identifying Patients with Specific Molecular Signature - Ana Aparicio

Details
Ana Aparicio discusses her work with aggressive variant prostate cancer and her group’s research using immunohistochemistry results and genomic analysis to identify patients with a specific molecular signature. The research concludes that this molecular signature appears to identify the people that benefit from the addition of carboplatin to cabazitaxel chemotherapy. People that have the signature...

Precision Oncology Program for Cancer of the Prostate (POPCaP) - Matthew Rettig

Details
Matt Rettig discusses POPCaP and his work involving the health of veterans with prostate cancer and ongoing clinical trials going on exclusively within the Veterans Health Administration (VA) system. The Precision Oncology Program for Cancer of the Prostate (POPCaP), a partnership between the VA and the Prostate Cancer Foundation (PCF) to create a system of excellence for prostate cancer in VA is...

Interpreting Phase III Clinical Trial Data - Susan Halabi

Details
During the 2019 Advanced Prostate Cancer Consensus Conference (APCCC 2019), Susan Halabi joined Alicia Morgans to help interpret the various ongoing stage III clinical trials in prostate cancer. Dr. Halabi shares the top errors we can avoid in subgroup analyses. Biographies: Susan Halabi, Ph.D., Professor of Biostatistics and Bioinformatics, Duke Cancer Institute, Durham, North Carolina, United St...

The Changing Landscape for Locally Advanced Prostate Cancer- Maria de Santis

Details
Maria de Santis and Chuck Ryan share a conversation on the rapidly changing landscape for the treatment of locally advanced prostate cancer. A focus of the discussion centers around the STAMPEDE data demonstrating benefit with the early use of abiraterone and the use of radiation. They also discuss the role of docetaxel in this evolving environment based on data from both STAMPEDE and CHAARTED dat...

Disparities and Outcomes in Men with Prostate Cancer - Susan Halabi, Mindy Hebert-DeRouen, and Daniel George

Details
At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Charles Ryan is joined by three physicians to discuss disparities and outcomes in men with prostate cancer. Drs. Susan Halabi, Mindy DeRouen, and Dan George shared highlights from their presentations from the PCF Scientific Retreat. Dr. Hebert-DeRouen shares details on the Disparities Research: Environment and multi oMics...

The IRONMAN - An International Registry for Men with Advanced Prostate Cancer - Dana Rathkopf

Details
At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) Dana Rathkopf and Alicia Morgans discuss the IRONMAN registry. Dana, a strong contributor to the IRONMAN registry trial, explains the goals of the registry and why it is so important for the personalization of patient care around the world. The IRONMAN registry is a population-based observational study currently in nine co...

Advancing Prostate Cancer Research - The Prostate Cancer Clinical Trials Consortium (PCCTC) - Sarah Wise

Details
Sarah Wise, the Director of Research Operations at the Prostate Cancer Clinical Trials Consortium (PCCTC) sits down with Alicia Morgans to talk about the PCCTC, what the goals of the organization are, the benefit of the organization to patients, and how physicians, clinicians, and researchers can support what they are trying to do. The Prostate Cancer Clinical Trials Consortium (PCCTC) was initiat...
email news signup